Comparative Pharmacology
Head-to-head clinical analysis: CENOBAMATE versus DILANTIN 125.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CENOBAMATE versus DILANTIN 125.
CENOBAMATE vs DILANTIN-125
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cenobamate is a tetrazole-derived anticonvulsant that modulates GABA A receptors, preferentially inhibiting the persistent sodium current and activating potassium currents (M-current). It also enhances GABA-mediated inhibition and reduces excitatory neurotransmitter release.
Phenytoin stabilizes neuronal membranes by promoting voltage-gated sodium channel inactivation, reducing high-frequency neuronal firing and seizure propagation.
Cenobamate 200 mg orally once daily initially, titrated weekly by 50 mg to a target dose of 400 mg once daily; maximum 400 mg/day.
300-400 mg per day orally in divided doses (e.g., 100 mg three times daily); loading dose 1 g orally divided into three doses given at 2-hour intervals, then 100 mg every 6-8 hours for first 24 hours.
None Documented
None Documented
The terminal elimination half-life is approximately 10-17 hours in adults. Steady-state is achieved within 2-3 days. In patients with moderate to severe hepatic impairment, half-life may be prolonged.
Terminal half-life: 7-42 hours (mean 22 hours) in adults; dose-dependent due to saturable metabolism. Steady-state reached in 7-10 days.
Renal excretion accounts for approximately 92% of the administered dose, with 62% as unchanged drug and 30% as metabolites. Fecal excretion is minimal (<2%).
Renal: 70% as metabolites (mainly HPPA glucuronide and sulfate), 5-10% as unchanged drug. Fecal: 30% (minor).
Category C
Category C
Anticonvulsant
Anticonvulsant